Federal Medical Marijuana Licenses Face High Risk Amid Ongoing Legal Battles

2026-10-14 politics

Washington, Tuesday, 13 October 2026.
A former drug official warned that issuing federal medical marijuana registrations during ongoing court challenges creates severe legal risks, as overturning the decision would force complex permit revocations.

Former DEA Official Warns of Regulatory Risks

On October 13, 2026, Matthew Strait, a former Deputy Assistant Administrator in the DEA’s Diversion Control Division, issued a public warning against granting federal Schedule III marijuana licenses prior to a resolution from a federal appeals court [1]. This statement was highlighted by Duane Boise, CEO of MMJ International Holdings, who noted that the warning signals significant regulatory and legal risks for state medical marijuana operators seeking federal DEA registrations while litigation against the government’s rescheduling order proceeds [1]. Strait explicitly stated, “I don’t think it would be wise for DEA to issue any registrations,” citing the risk that if the D.C. Circuit invalidates the April 2026 rescheduling order after registrations have been granted, the DEA would face a cumbersome and burdensome administrative process to revoke those registrations [1]. As of October 12, 2026, no publicly verified DEA decision exists to enforce a blanket suspension of registrations, but there is increasing industry uncertainty regarding whether DEA Administrator Terrance Cole will proceed with registrations or delay them to avoid potential future revocation proceedings [1].

Legal Challenges and Political Context

The current regulatory framework stems from an April 2026 order issued by the federal government, specifically an announcement on April 23 by then-U.S. Acting Attorney General Todd Blanche to immediately reschedule state-licensed medical cannabis from Schedule I to Schedule III under the Controlled Substances Act [6]. This action was part of a Trump administration order intended to provide medical cannabis businesses with Section 280E tax relief and federal recognition of accepted medical use [6]. However, the order is currently being challenged by entities including MMJ International Holdings regarding statutory authority and procedural implementation [1]. On September 9, 2026, the U.S. Court of Appeals for the D.C. Circuit denied a stay request for the rescheduling order, allowing the framework to remain legally operative despite ongoing judicial review [1]. As of October 12, 2026, the rescheduling order remains in effect, though it is subject to ongoing litigation in the D.C. Circuit under consolidated cases Nos. 26-1106, 26-1130, and 26-1136 [1].

Market Reaction to Litigation Delays

Financial markets have responded sensitively to the legal uncertainties surrounding the rescheduling effort. On September 29, 2026, DEA Chief Judge Derek Julius issued a stay on the federal cannabis rescheduling case to determine whether to reopen the record, requiring the government and other parties to respond by October 13, 2026 [5]. Following the stay announcement, the AdvisorShares Pure US Cannabis ETF (MSOS) declined approximately 8% in after-hours trading, while Trulieve Cannabis (TRLV) shares dropped roughly 9% in extended hours after closing at $12.41 on September 29, 2026 [5]. Despite the volatility, TRLV stock has experienced a 43% gain year-to-date as of October 12, 2026, and retail sentiment regarding TRLV and MSOS on Stocktwits remains in bullish territory despite the DEA litigation stay [5]. Some market observers noted that broader rescheduling appears less likely in the immediate term, though others maintain that a rescheduling will come in the future [5].

Administrative Processes and Future Deadlines

Despite the legal warnings, the DEA’s Diversion Control Division launched a new application process on October 5, 2026, for medical cannabis manufacturers, distributors, and analytical labs wishing to register under Schedule III status [6]. State-licensed medical cannabis businesses can use the new Form 225 application process to register under the Controlled Substances Act, although the 60-day window for expedited registration concluded in June [6]. Appellate briefing schedules are proposed to extend through February 2027, with oral arguments potentially occurring before the court’s summer 2027 recess, though the status of this briefing schedule remains pending and ongoing [1][alert! ‘briefing schedule status pending/ongoing’]. The federal effort to move marijuana from Schedule I to Schedule III remains stalled in terms of finality, with another critical deadline having approached on October 13, 2026 [4]. The final legal effect depends on the outcome and scope of the federal rulemaking process and the ongoing judicial review [3].

Sources

Cannabis regulation DEA rescheduling